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not significantly different between the two treatment groups from baseline to end 
of treatment. However, there was a statistically significant improvement in Pain 
QLQ-C30 score from baseline to week 3 (OR= 3.14, p= 0.036) and week 6 (OR= 3.33, 
p= 0.034) in the metronomic arm compared with the cisplastin arm. ConClusions: 
Understanding the impact of different treatment options on changes in QoL over 
time can not only aid physicians in communication with patients but also assist 
in the design of interventions that focus on rehabilitation of patients with head 
and neck cancer.
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objeCtives: To monitor changes in health related quality of life (HRQoL) among 
advanced stage non small cell lung cancer (NSCLC) patients receiving oral gefi-
tinib. Methods: An observational study was conducted at the Tata Memorial 
Hospital, Mumbai, India, among stage-IV NSCLC patients who were > 18 years, had 
failed conventional chemotherapy, had EGFR mutation reports available, and were 
scheduled to receive oral gefitinib 250 mg OD treatment. Patients who met the 
inclusion criteria and agreed to participate in the study were recruited between 
January 1, 2010 and June 30, 2012. In addition to recording demographic and baseline 
clinical characteristics, patients were asked to rate their HRQoL using the European 
Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC 
QLQ-LC13 questionnaires (Indian versions) at baseline and at every two months 
till the patient developed progressive disease or deteriorated in performance sta-
tus. Results: A total of 167 patients participated in the study. The mean age of 
study participants was 58.5 years (S.D.± 11.8). About 37.8% patients had a history 
of any kind of tobacco use. Significant improvements in overall quality of life were 
observed from baseline at week 16 (p= 0.001), week 24 (p= 0.02), and week 32 (p= 0.03). 
Furthermore, lung cancer symptom score (QLQ-LC-13) significantly decreased at 
week 8 (p= 0.019) and week 16 (p< < 0.01) as compared to baseline. Compared to 
baseline, pain in the arm and shoulder (QLQ-LC-13) decreased at week 8 (p= 0.008) 
and week 16 (p= 0.0025), as did pain in chest (QLQ-LC-13) at week 8 (p= 0.049) and 
week 16 (p= 0.003). ConClusions: Gefitinib has not only shown a favorable toxicity 
profile but it has also demonstrated significant improvements over time in overall 
QoL, as well as, on domains such a symptom relief and pain. Therefore, Gefitinib 
could be considered as a viable treatment option in patients with advanced NSCLC.
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objeCtives: Health-related quality of life (HRQoL) is essential in treatment deci-
sions for metastatic breast cancer (mBC), therefore, it’s important to understand 
the impact of treatment on patient-reported outcomes (PRO) in a real-world set-
ting. This study aims to characterize the impact of mBC and cancer treatments on 
HRQoL, treatment satisfaction and daily productivity from the patient perspec-
tive. Methods: This is a cross-sectional survey of 360 patients with mBC (US, 
n= 200; EU, n= 160). Post-menopausal women aged ≥ 50 years, with hormone receptor 
positive (HR+), HER2-negative (HER2-) mBC, currently using hormonal therapy (HT) 
or using chemotherapy (CT) for ≤ 1 year were recruited. The Functional Assessment 
of Cancer Therapy–Breast (FACT-B), Work Productivity and Activity Impairment, 
Cancer Treatment Satisfaction Questionnaire (CTSQ), patient-centric questions 
related to mBC, demographics, and adverse events (AEs) were assessed across CT 
and HT users. Multivariate analyses compared CT vs. HT with adjustments for 
demographics, comorbidities, and disease/treatment related measures. Results: 
Among the 360 patients, 53% (n= 191) reported CT and 47% (n= 169) reported HT 
use. Patient characteristics were generally similar between treatment cohorts with 
an average age of 58.3 years (SD= 6.3). HT users reported higher FACT-B scores (78.0 
vs. 70.1, p< 0.001), higher scores on the FACT-B subscales (physical, emotional and 
functional well-being, and breast cancer, p< 0.05 for all), greater satisfaction with 
treatment (subscale of the CTSQ; 74.1 vs. 67.2, p< 0.001), and better feelings about 
side-effects (subscale of the CTSQ; 48.2 vs. 41.6, p< 0.001). HT users reported less 
bother with treatment AEs (0-5 scale, 1.0 vs. 1.3, p< 0.001) and less activity impair-
ment compared with CT (52.6% vs. 60.8%, p< 0.001). ConClusions: Findings sug-
gest that HT is associated with better HRQoL, greater treatment satisfaction, less 
treatment related AEs, and less activity impairment compared with CT in 1st line 
mBC. These findings should be taken into consideration while making treatment 
decisions for HR+/HER2- mBC.
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objeCtives: The COMPLEMENT 1 trial demonstrated significantly better progres-
sion-free survival with ofatumumab combined with chlorambucil (O+CHL) [22.4 
months] versus chlorambucil alone (CHL) [13.1 months] in patients with chronic 
lymphocytic leukemia . The impact on health-related quality of life (HRQoL) was also 
assessed. Methods: 447 previously untreated patients were randomized to receive 
3-12 cycles of O+CHL or CHL. The European Organization for Research and Treatment 
of Cancer (EORTC) QLQ-C30 and QLQ-CLL16 were administered at screening (base-
line), day 1 of cycles 4, 7, 10 and post-therapy. The pre-specified HRQoL outcomes 
were changes from baseline during and post therapy, and treatment differences in 
the two arms for Global Health Scale (GHS) of the QLQ-C30 and the Fatigue scale 
of the QLQ-CLL16. For treatment comparisons, mixed-model repeated measures 
(MMRM) analysis of covariance was used. Results: 428 patients completed at least 
one HRQoL assessment; with a median of 6 treatment cycles, cycle 10 had too few 
patients to analyze. For GHS, patients had improvements greater than the minimally 
important difference of 5 points for the CHL arm (Cycle 7) and for the O+CHL arm 
(Cycles 4 and 7). For the Fatigue scale, patients showed improvement from base-
line in both arms at Cycles 4 and 7. Most scales showed numerical improvements 
in both arms; exceptions were four scales in the CHL and two in the O+CHL arm. 
Post therapy, there were positive numerical changes from the last on-treatment 
visit in both arms for GHS and Fatigue scales. MMRM analysis showed no differ-
ences between treatment arms for GHS or Fatigue scales. ConClusions: Patients 
receiving either O+CHL or CHL experienced improvements in HRQoL during therapy. 
Off treatment, patients continued to maintain or increase the improvements. The 
addition of ofatumumab to chlorambucil did not negatively impact HRQoL and may 
improve certain aspects of patients’ HRQoL during and after treatment.
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objeCtives: Cancer is related to lower health-related quality of life (HRQoL). 
However, little evidence exists regarding the marginal decrease in HRQoL by the 
presence of comorbid anxiety and mood disorders (bipolar and depressive disorders) 
among cancer survivors based on U.S population-based research. The objective of 
the study was to determine whether comorbid anxiety and mood disorders were 
associated decreased HRQoL among cancer survivors. Methods: This cross-sec-
tional study used data from the 2011 Medical Expenditure Panel Surveys (MEPS). 
The independent variable was the presence of anxiety and/or mood disorders, and 
the dependent variable was HRQoL, which was measured using the SF-12 physical 
health composite scale (PCS) and mental health composite scale (MCS). Descriptive 
statistics, chi-square tests, and generalized linear models (GLM) were used for analy-
ses. Results: Among the estimated 17,987,639 cancer survivors, 9.4% had anxiety 
but not mood mood disorders, 11.4% had mood disorders but not anxiety, 3.8% 
had both anxiety and mood disorders, and 75.7% had neither anxiety nor mood 
disorders. The chi-square tests shows that the prevalence of anxiety and/or mood 
disorders was significantly different by age groups (p< 0.001), gender (p= 0.002), 
and perceived health status (p< 0.001), while it was not significantly different by 
race, insurance type, marital status, region, family income, and the presence of 
comorbidity. In the GLMs analyzing anxiety mood disorders separately, anxiety and 
mood disorders were both significantly associated with lower PCS scores (p= 0.002 
and p< 0.001) and MCS scores (both p< 0.001). After controlling for demographic 
and clinical factors, anxiety was not significantly associated with lower PCS scores 
(p= 0.235), but was associated with lower MCS scores (p= 0.005), and mood disorders 
were still significantly associated with both lower PCS (p= 0.006) and MCS (p< 0.001) 
scores. ConClusions: Both anxiety and mood disorders were independently asso-
ciated with lower HRQoL among cancer survivors, but when controlling for other 
factors, mood disorders showed no association with the PCS.
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objeCtives: Evaluate changes in health related quality of life (HRQoL) in patients 
with metastatic head and neck cancer randomized to receive either metronomic 
(methotrexate and celecoxib) or cisplatin chemotherapy. Methods: Patients older 
than 18 years, Karnofsky performance score of > 70 and diagnosed with metastatic, 
locally advanced inoperable or recurrent head and neck cancer not amenable to 
surgery or radiation were randomized (1:1) to receive of metronomic or 6 cycles of 
cisplatin chemotherapy. All patients were recruited from the Tata Memorial Hospital 
(TMH), Mumbai, India. In addition to demographic and baseline clinical character-
istics, patients were asked to rate their HRQoL using the European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-H&N35 
questionnaires (Indian versions) at baseline and at the end of each chemo-cycle 
(every three weeks) till the end of study (week 18) or early termination. Results: 
Of the 110 patients screened, 87 agreed to participate in the study. Mean age of the 
study population was 47.5 years (S.D.± 10.04) for the metronomic group and 47.2 
years (S.D.± 9.89) for the cisplatin group. Oral cavity was the primary site of cancer 
(metronomic arm: 77.8%; cisplatin arm: 71.4%). About 57.8% and 45.2% patients 
had a history of tobacco use in both treatment arms. Overall quality of life was 
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objeCtives: Thyroid cancer is a rare and heterogeneous disease. While many 
patients have a good prognosis, a subset of 5-20% experience recurrence and pro-
gressive disease. Resource use in patients with thyroid cancer, and specific subtypes 
such as medullary thyroid cancer (MTC) and differentiated thyroid cancer (DTC), are 
not well characteristised; therefore, the study evaluated characteristics, health care 
utilization and costs in a commercially insured US population. Methods: A retro-
spective observational cohort analysis, using the HealthCore Integrated Research 
Environment (HIRE) for the period 01/1/2006 through 8/31/2012, was conducted. 
Cases were defined by at least 2 diagnoses of thyroid cancer within 60 days, and 
algorithms were developed to further sub-classify patients into histologic groups. 
Baseline (defined as 12 months prior to first diagnosis) and post-diagnosis charac-
teristics and costs were calculated. Results: 6,823 thyroid cancer patients were 
identified, including 280 MTC, 3,238 DTC. Mean age was 49.2 years and less than 
1% were children; 76% of patients were female. At baseline, the most common 
comorbidities were infection (45%), hypertension (33%), hypothyroidism (32%) and 
chronic fatigue (21%). Resource use and medication utilization was substantially 
different between subgroups. 63% of all patients had at least one post-diagnosis 
hospitalisation, which was higher in DTC (77%) and MTC (70%) than uncatego-
rised patients. Around 30% of all patients had ≥ 1 emergency department visit. 
DTC patients filled significantly more thyroid specific medications. Patients with 
advanced disease(N= 2,399) had more comorbidities, greater health care utilization 
and costs. Total health care costs per patients year across all patients was $17K, 
and were significantly higher in patients with MTC ( $24K), and those with any 
advanced thyroid cancer ($46K). ConClusions: Thyroid cancer is a costly and 
resource intensive disease. While MTC patients incurred greater total health care 
costs, driven largely by hospitalizations and outpatient visits, advanced disease was 
associated with the highest resource utilization and costs.
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objeCtives: Assess the annual number of patients with MCL who relapse or are 
refractory to first line therapy in selected European countries. Methods: A sys-
tematic literature review, aiming to identify and summarize all evidence related 
to outcomes of current treatment options for MCL was conducted. A comprehen-
sive literature search of two databases (PUBMED and Cochrane) from 2005-2014, 
and proceedings from major hematology/oncology conferences was undertaken. 
In addition, data from various cancer registries, surveillance and cohort studies 
were analyzed. Incidence and prevalence of MCL was calculated and patient out-
comes (e.g. overall response rate [ORR] and progression-free survival [PFS]) were 
summarized. Data analysis was stratified for subpopulations by age, ECOG per-
formance status and first-line treatment options available in the countries under 
study (Belgium, France, Germany, Italy, The Netherlands, Poland, Spain, Sweden and 
the UK). Results: The proportion of MCL as a subtype of NHL ranges from 2.0% to 
7.1%. Minimum and maximum estimates of the newly diagnosed total patients with 
MCL in Europe range from 3,219 to 6,177 patients (0.6 – 1.2 per 100,000) in 2012, and 
the estimated prevalence ranges from 9,014 to 17,296 (1.8 – 3.4 per 100,000). Overall 
response (OR) rates after first line immunochemotherapy in MCL patients ranges 
from 63% to 97%, complete response (CR) rates range from 15% to 96%. Progression-
free survival (PFS) ranges from 16 months to 83 months. Based on evidence derived 
from this review, the steady-state prevalence of patients with relapsed or refractory 
MCL ranges from 1,778 – 8,799 patients annually, requiring second line treatment in 
the countries under study. ConClusions: Despite improved treatment alternatives 
and improved outcomes in patients with MCL, remission duration is still short and 
the proportion of patients needing 2nd line and subsequent lines of therapy is high.
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objeCtives: To determine whether a new cancer diagnosis affects drug therapy for 
diabetes among Medicare beneficiaries. Methods: We identified diabetes patients 
from a 5% random sample of Medicare beneficiaries enrolled in Medicare Part D in 
2007 and 2008. We then identified the subset with newly diagnosed cancer between 
January and December 2007 (N= 4,457). The comparison group represented ben-
eficiaries with diabetes who had no evidence of cancer during the study period 
(N= 29,187). Use and adherence with oral hypoglycemic agents, RAAS-inhibitors, and 
statins were tracked during 6-month periods prior to and after cancer diagnosis and 
a matching index date for non-cancer controls. Monthly adherence was measured 
by the percentage of days covered (PDC). We estimated difference-in-difference-in-
difference (DDD) equations to assess the independent impact of cancer diagnosis 
and poor prognosis (died in month 7 to 12 after index date) on PDC controlling for 
individual characteristics. Results: We found that adherence declined between 
the pre-index and post-index periods for all drug classes with the sharpest drop 
evident among cancer patients who subsequently died in month 7 to 12. Depending 
on drug class, a cancer diagnosis reduced PDC by 4.7% to 6.1% among survivors and 
by 7.6% to 16.4% for decedents. Among non-cancer controls, the declines ranged 
between 1.5% and 3.2% (survivors) and between 5.7% and 9.1% (decedents). Similarly, 
objeCtives: Major discordance for the initial diagnosis could induce a strong 
impact on therapeutic strategies and costs. To deal with this problem, the cost of dis-
cordant diagnoses was assessed in sarcoma patients treated in France. Methods: 
This multicenter analysis was performed retrospectively using prospective-imple-
mented databases. Inclusion criteria were sarcoma patients with a discordant 
diagnosis after histological review performed within the RRePS network in 2010. 
Diagnoses were considered discordant when the final diagnosis was not categorized 
in the same way as the initial finding, as defined by the World Health Organization 
Classification. Therapeutic strategies related to the diagnosis were based on patient 
and disease characteristics and using national or international guidelines when 
available. All the strategies were defined by the authors. Related costs were assessed 
for initial diagnosis inducing specific managements and the management expected 
with the restored diagnosis after second opinion by pathologist expert. Costs were 
assessed according to the French National Health Insurance (NHI) perspective. The 
time horizon included initial treatments and a one year follow-up period. All costs 
were expressed in Euros 2013. Uncertainty was assessed by probabilistic sensitivity 
analysis. Results: Out of the 2,425 patients that underwent histological review, 
341 patients had a major discordance in their diagnosis (14.1%). Ten patients were 
excluded due to missing data. The costs of the therapeutic strategies for the initial 
diagnosis reached € 2,186,816 for the NHI. More precisely, costs [95% CI] reached: 
€ 696,452 [€ 535,745–€ 857,159] for gastrointestinal stromal tumors (GIST) (n= 35) 
confounded with non-GIST; € 695,755 [€ 547,822–€ 843,688] for sarcoma (n= 74) con-
founded with non-sarcoma malignant tumors; € 533,987 [€ 450,333–€ 617,641] for sar-
coma confounded with benign tumors (n= 117). ConClusions: This study revealed 
the high cost of the therapeutic strategies resulting from misdiagnosis. Based on 
the publication of Lapeyrere, where the cost per histological review reached € 228, 
histological reviews would result in a cost saving of € 1,633,916 in 2010.
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objeCtives: Assess the annual number of patients with chronic lymphocytic leu-
kemia (CLL)/small cell lymphocytic leukemia (SLL) who relapse or are refractory to 
first line therapy in selected European countries. Methods: A systematic litera-
ture review, aiming to identify and summarize all evidence related to outcomes of 
current treatment options for CLL/SLL was conducted. A comprehensive literature 
search of two databases (PUBMED and Cochrane) from 2005-2014, and proceed-
ings from major hematology/oncology conferences was undertaken. In addition, 
data from various cancer registries, surveillance and cohort studies were analyzed. 
Incidence and prevalence of CLL/SLL was calculated and patient outcomes (e.g. 
overall response rate [ORR] and progression-free survival [PFS]) were summarized. 
Data analysis was stratified for subpopulations by age, ECOG performance status, 
presence of del17p and first-line treatment options available in the countries under 
study (Belgium, France, Germany, Italy, The Netherlands, Poland, Spain, Sweden 
and the UK). Results: The incidence of CLL/SLL ranges from 4.9 to 6.9 per 100,000 
in the countries under study. The estimated number of newly diagnosed patients 
each year with CLL/SLL in Europe ranges from 19,383 to 26,411. ORR after first line 
chemo-immunotherapy ranged from 63% to 95%, with complete response rates 
ranging from 5% to 47%. PFS rates ranged from 19 to 80 months. Based on evidence 
derived from this review, the steady-state prevalence of patients with relapsed or 
refractory CLL/SLL resulted in 9,174 to 19,579 patients annually, requiring second 
line treatment in the countries under study. ConClusions: CLL/SLL represents 
the largest adult leukemia in the western world. This systematic literature review 
identified the significant number of patients failing first-line therapy with relapsed 
or refractory disease. Despite the improved response rates achieved in the last dec-
ade, duration of response varies, with some patients having short durations only. 
Therefore, further improvement in treatment options is required.
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objeCtives: Prostate-specific antigen (PSA) monitoring following a diagnosis of 
prostate cancer remains controversial. We sought to describe results and pre-
dictors of PSA monitoring among non-metastatic prostate cancer patients with 
employer sponsored health insurance. Methods: Male patients with ≥ 2 medi-
cal claims with a diagnosis of prostate cancer (ICD-9-CM code 185.00) between 
1/1/2008-4/30/2013 (index date) were evaluated in Truven Health MarketScan 
Treatment Pathways 3.0. Included patients had ≥ 6 mo continuous enrollment 
prior to and ≥ 24 mo of continuous enrollment following their index date and 
no diagnosis of metastatic cancer anytime during the study period. Receipt of 
PSA laboratory tests following cancer diagnosis was evaluated in the follow-up 
period. Results: In total, 7,893 men met the inclusion criteria. 6,558 (83%) had 
a PSA test post-index and 69% of them had a second PSA. Mean days from index 
to first and second PSA were 372 and 220 days, respectively. Mean age was 59 
years among those with a PSA test and 72 years among those without. Of the 
2,245 patients with an available test result, 85% had normal PSA scores (77% 0 to 
< 2 ng/mL; 8% 2 to < 4 ng/mL), while 4.4% were ≥ 10 ng/mL. PSA was normal for 
89% (81% 0 to < 2 ng/mL; 8% 2 to < 4 ng/mL) with a 2nd PSA, while 3% were ≥ 10 
ng/mL. Men without a PSA test were more likely to have comorbid hypertension 
(74% vs. 20%), hyperlipidemia (60% vs. 20%), and diabetes (35% vs. 9%) than those 
with a test. ConClusions: The majority of men had at least 1 PSA test within 
the first year following their diagnosis, and the majority of those results were in 
the normal range. Monitoring appears to be more common among healthier men. 
Future research should explore whether monitoring results in better outcomes.
